Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA2 | P16389 | 1/20 | 0.64 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.64 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.64 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615123 | 0.89 | KCNA3 (0.51) | KCNA2KCNA5KCNA1KCNA3 | |
| SCHEMBL3607797 | 0.88 | KCNA2 (0.69) | KCNA2KCNA5KCNA1KCNA3 | |
| SCHEMBL3612488 | 0.88 | KCNA3 (0.64) | KCNA2KCNA5KCNA1KCNA3 | |
| SCHEMBL3613546 | 0.87 | KCNA3 (0.52) | KCNA2KCNA5KCNA1KCNA3 | |
| SCHEMBL3608600 | 0.86 | KCNA3 (0.51) | KCNA2KCNA5KCNA1KCNA3 | |
| SCHEMBL14221359 | 0.86 | KCNA3 (0.51) | KCNA2KCNA5KCNA1KCNA3 | |
| SCHEMBL13408305 | 0.86 | KCNA3 (0.51) | KCNA2KCNA5KCNA1KCNA3 | |
| SCHEMBL3611946 | 0.85 | KCNA3 (0.52) | KCNA2KCNA5KCNA1KCNA3 | |
| SCHEMBL13408333 | 0.84 | KCNA3 (0.52) | KCNA2KCNA5KCNA1KCNA3 | |
| SCHEMBL3606053 | 0.84 | KCNA3 (0.49) | KCNA2KCNA5KCNA1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309545-B2 | Benzofuran potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-11-13 | — | — | US | disclosed |
| US-8309545-B2 | Benzofuran potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-11-13 | — | — | US | disclosed |
| US-8309545-B2 | Benzofuran potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-11-13 | — | — | US | disclosed |
| US-8217189-B2 | Chromenone potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-07-10 | — | — | US | disclosed |
| US-8217189-B2 | Chromenone potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-07-10 | — | — | US | disclosed |
| US-8217189-B2 | Chromenone potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-07-10 | — | — | US | disclosed |
| US-20100087430-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-04-08 | — | — | US | disclosed |
| US-20100087430-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-04-08 | — | — | US | disclosed |
| US-20100087430-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-04-08 | — | — | US | disclosed |
| US-20090298931-A1 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-12-03 | — | — | US | disclosed |
| US-20090298931-A1 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-12-03 | — | — | US | disclosed |
| US-20090298931-A1 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-12-03 | — | — | US | disclosed |
| WO-2008040057-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040057-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040058-A1 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040058-A1 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087430-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNK3 | KCNA2 31/4885KCNA5 21/4885KCNA1 14/4885 |
| US-20090298931-A1 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNK3, KCNA3, KCND3 | KCNA2 34/4885KCNA5 32/4885KCNA1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.